Esophageal cancer responsive to the combination of immune cell therapy and low-dose nivolumab: two case reports

BACKGROUND: Blocking the programmed death 1 pathway by immune checkpoint inhibitors induces dramatic antitumor activity in patients with malignant tumors. However, the clinical response to immune checkpoint inhibitors remains limited owing to the patients’ immunological status, such as the number of...

Descripción completa

Detalles Bibliográficos
Autores principales: Takimoto, Rishu, Kamigaki, Takashi, Gotoda, Takuji, Takahashi, Toshimi, Okada, Sachiko, Ibe, Hiroshi, Oguma, Eri, Goto, Shigenori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028114/
https://www.ncbi.nlm.nih.gov/pubmed/33827668
http://dx.doi.org/10.1186/s13256-020-02634-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028114/
https://www.ncbi.nlm.nih.gov/pubmed/33827668
http://dx.doi.org/10.1186/s13256-020-02634-z

Ejemplares similares